Therefore, the pellets of the present invention may be effectively used in an orally administered pellet formulation containing tacrolimus as an active ingredient.LEE HEE-YUB
The invention relates to a method for the production of active ingredient-containing pellets by the steps of a) suspending or dissolving a pharmaceutical active ingredient in a dispersion, which contains a cationic copolymer, b) dropping said dispersion, containing the pharmaceutical active ingredient ...
The bioavailability of the active ingredient is a crucial factor in drug development, and although certain biomolecules possess intervening properties in organisms, their application is often limited by low bioavailability [61]. Low bioavailability is typically attributed to low water solubility or low me...
(4) a preventive and/or treatment medicine for diseases attributable to stress, which comprises the compound represented by formula (I) as an active ingredient. BACKGROUND ART In 1977, mitocondorial benzogeazepin receptor (hereafter, it is abbreviated as MBR.) was identified as a receptor that...
Pharmaceutical preparations for the treatment of hyperacidity in body fluids comprising as active ingredient a compound of the formula: wherein each of R, R and R represents a hydroxyl group or an amino group optionally substituted by l... ILANI ASHER,LICHTSTEIN DAVID,SOMER HAIM,... 被引量...
CONSTITUTION: A sustained release pellet comprises: a pharmacologically active ingredient layer containing tacrolimus as a main ingredient and hydroxypropyl methyl cellulose as a binder; a primary pharmaceutically inactive ingredient layer(C1) which covers the pharmacologically active ingredient layer and ...
The present invention relates to a pharmaceutical composition for preventing or treating immune diseases, comprising tacrolimus and vitamin D as an active ingredient. According to the present invention, the tacrolimus and the vitamin D have excellent effects in inhibiting the differentiation into cytotoxic...
Identification of gallic acid as a active ingredient of Syzygium aromaticum against tacrolimus-induced damage in renal epithelial LLC-PK1 cells and rat kidneyFK506Gallic acidNephrotoxicityTacrolimusTacrolimus (FK506), a calcineurin inhibitor, is an effective immunosuppressive agent mainly used to lower ...
In a non-limiting embodiment, there is provided a pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising an IL-31 antagonist as an active ingredient, wherein the IL-31 antagonist is repeatedly administered in equal amounts at the same dosing interval to a subject...
A sprayable film-forming pharmaceutical composition for dermal application comprises at least one therapeutically active ingredient dissolved in a pharmaceutically acceptable propel